---
schema_version: "secwatch.filing_event.v1"
accession: "0001217234-23-000224"
form_type: "8-K"
ticker: "CDNA"
cik: "0001217234"
company_name: "CareDx, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T08:44:28.795194+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CareDx Q3 revenue $67.2M (-15% YoY); net loss $23.5M; raises FY2023 guidance to $274-278M

## Summary
- Revenue $67.2M (-15% YoY); testing services $47.8M (-26% YoY).
- Net loss $23.5M ($0.43 loss per share) vs $16.9M loss ($0.32 loss per share) in Q3 2022; non-GAAP loss $9.6M.
- Adjusted EBITDA loss $10.9M, compared to loss $2.5M in Q3 2022.
- Raised full-year 2023 revenue guidance to $274-278M from prior outlook.
- SEC concluded inquiry with no enforcement action; Medicare coverage for HeartCare and AlloSure Lung.

## SEC filing metadata
- accession: 0001217234-23-000224
- form_type: 8-K
- ticker: CDNA
- cik: 0001217234
- company_name: CareDx, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1217234/000121723423000224/0001217234-23-000224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1217234/000121723423000224/cdna-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001217234-23-000224
- JSON: https://secwatch.observer/filing/0001217234-23-000224.json
- Plain text: https://secwatch.observer/filing/0001217234-23-000224.txt

## Key facts
- Earnings Releases
  CareDx, Inc. reported the third quarter ended September 30, 2023 results: revenue $67.2 million, net income $23.5 million, EPS $0.43. Guidance raised.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $67.2 million
  - Net income: $23.5 million
  - EPS: $0.43
  - Guidance: raised
  - Result: reported results
  source text: for transplant patients and caregivers -- today reported financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights • Reported revenue of $67.2 million, an increase of 7% over the second quarter of 2023, excluding approximately $7.8 million related to Medicare claims billing that were held over from the first quarter of 2023 and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1217234/000121723423000224/0001217234-23-000224-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.